Literature DB >> 1904071

Biological and biochemical characterization of a factor produced spontaneously by adherent cells of human immunodeficiency virus-infected patients inhibiting interleukin-2 receptor alpha chain (Tac) expression on normal T cells.

A Ammar1, C Cibert, A M Bertoli, V Tsilivakos, C Jasmin, V Georgoulias.   

Abstract

Adherent cells from human immunodeficiency virus (HIV)-infected subjects but not from normal blood donors, patients with Gram-positive or -negative bacteremia, active tuberculosis, toxoplasmosis, pulmonary aspergillosis, and cytomegalovirus infection produce spontaneously an activity which inhibits alpha chain of interleukin-2 (Tac) expression and interleukin 2 (IL-2) production by normal activated T cells and IL-2 production by these cells. A similar biologic activity was detected in culture supernatants of in vitro HIV-I-infected normal adherent and leukemic U937 cells. Tac-inhibitory activity is not cytotoxic and it could be detected in serum-free conditioned media. Recombinant granulocyte/macrophage colony-stimulating factor and phorbol myristate acetate stimulation of patients' and normal adherent cells did not enhance specifically the production of the Tac inhibitor. Biologically active conditioned media did not contain infectious virus as well as secreted p24, gp120 viral proteins; the biologic activity could not be abolished by anti-p24, anti-gp120, and anti-nef monoclonal antibodies or human purified polyclonal anti-HIV IgG. Gel filtration of conditioned media followed by anion exchange chromatography resulted in a 1,200-fold degree of purification and revealed that the biologically active molecule was cationic. Sodium dodecyl sulfate polyacrylamide gel electrophoresis of this fraction and gel elution of the proteins showed that the biologic activity was associated with a 29-kD protein which was distinct from alpha- or gamma-interferon, tumor necrosis factor-alpha, and prostaglandin E2. The above findings demonstrate the production of inhibitory factor(s) during HIV infection, which might be involved in the pathogenesis of the patients' immune defect.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1904071      PMCID: PMC296961          DOI: 10.1172/JCI115235

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  A rapid, sensitive, and specific method for the determination of protein in dilute solution.

Authors:  W Schaffner; C Weissmann
Journal:  Anal Biochem       Date:  1973-12       Impact factor: 3.365

Review 2.  NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations.

Authors:  A S Fauci; A M Macher; D L Longo; H C Lane; A H Rook; H Masur; E P Gelmann
Journal:  Ann Intern Med       Date:  1984-01       Impact factor: 25.391

3.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

4.  Immunologic abnormalities in homosexual men. Relationship to Kaposi's sarcoma.

Authors:  R E Stahl; A Friedman-Kien; R Dubin; M Marmor; S Zolla-Pazner
Journal:  Am J Med       Date:  1982-08       Impact factor: 4.965

5.  Characteristics of immune interferon produced by human lymphocyte cultures compared to other human interferons.

Authors:  M J Valle; G W Jordan; S Haahr; T C Merigan
Journal:  J Immunol       Date:  1975-07       Impact factor: 5.422

6.  Immunoregulatory lymphokines of T hybridomas from AIDS patients: constitutive and inducible suppressor factors.

Authors:  J Laurence; L Mayer
Journal:  Science       Date:  1984-07-06       Impact factor: 47.728

7.  Depressed interleukin 2 receptor expression in acquired immune deficiency and lymphadenopathy syndromes.

Authors:  H E Prince; V Kermani-Arab; J L Fahey
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

8.  Soluble suppressor factors in patients with acquired immune deficiency syndrome and its prodrome. Elaboration in vitro by T lymphocyte-adherent cell interactions.

Authors:  J Laurence; A B Gottlieb; H G Kunkel
Journal:  J Clin Invest       Date:  1983-12       Impact factor: 14.808

9.  Interleukin-2 production and response to exogenous interleukin-2 in a patient with the acquired immune deficiency syndrome (AIDS).

Authors:  G J Hauser; T Bino; H Rosenberg; V Zakuth; E Geller; Z Spirer
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

10.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

View more
  3 in total

1.  A factor from CD8 cells of human immunodeficiency virus-infected patients suppresses HLA self-restricted T helper cell responses.

Authors:  M Clerici; E Roilides; C S Via; P A Pizzo; G M Shearer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

2.  Human immunodeficiency virus-infected adherent cell-derived inhibitory factor (p29) inhibits normal T cell proliferation through decreased expression of high affinity interleukin-2 receptors and production of interleukin-2.

Authors:  A Ammar; Y Sahraoui; A Tsapis; A M Bertoli; C Jasmin; V Georgoulias
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

Review 3.  Interleukin-2 and human immunodeficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement.

Authors:  A Kinter; A S Fauci
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.